Crypto Has Entered Its Fourth Stage Of Adoption, Industry Exec Says – Forbes

Metal Pay CEO Marshall Hayner mentioned bitcoin's growing role as an inflation hedge, while early ... [+] bitcoin investor Erik Finman sees the asset's recent price correction as healthy.

Bitcoin (BTC) had a standout year in the price category last year, rising from $3,870 in March, all the way past its 2017 record highs near $20,000. By January 2021, cryptos pioneer asset found itself priced at almost $42,000 per coin. Bitcoin also gained a notable amount of adoption in the latter half of 2020 as a number of mainstream companies, such as MicroStrategy MSTR and MassMutual, bought large amounts of the asset. Marshall Hayner, the CEO and founder of digital asset payment solution Metal Pay, said he thinks BTC has entered an acceptance stage on its adoption journey.

Bitcoin has reached all-time highs over the past few months, and with this meteoric rise, institutions, hedge funds, and major corporations have begun to add digital assets to their balance sheet, Hayner told me in a January 26 message. As the oldest, most liquid, and most well-known cryptocurrency, bitcoin is rapidly becoming a hedge against rampant inflation of fiat currency (USD, EUR), he said. This is what I'm calling the fourth wave of cryptocurrency adoption, he explained. The first three waves were exuberance, speculation, utility and finally acceptance.

[Ed note: Investing in cryptocoins or tokens is highly speculative and the market is largely unregulated. Anyone considering it should be prepared to lose their entire investment.]

Launched in January 2009, bitcoin started out worth virtually nothing in U.S. dollar terms. In 2010, programmer Laszlo Hanyecz famously paid 10,000 BTC for two pizzas. The digital asset has obviously risen significantly in price since then, surpassing milestone landmarks of $1, $100, $1,000 and $10,000 through the years. Along the way, parties have created thousands of other cryptocurrencies, many of which hold varying value propositions, although some industry participants, known as bitcoin maximalists, argue bitcoin as the only option.

Bitcoin has gained significant traction over the past year as a number of mainstream financial players unveiled their positions in the asset, making BTC allocation more commonplace than years prior. MicroStrategy allocated more than $1 billion of capital toward bitcoin. Among a number of other entities who put sizable amounts of money toward bitcoin, MassMutual spent $100 million on the digital asset.

In October 2020, payments giant PayPal PYPL also furthered crypto adoption when it announced the addition of bitcoin, ethereum, litecoin and bitcoin cash to its platform.

As we see major fintech firms like PayPal adding cryptocurrency and the first wave of national crypto banks under the OCC we are reaching mass acceptance and understanding of the true value of bitcoin and cryptocurrency, Hayner said. In July 2020, national banks received the ok from the U.S. Office of the Comptroller of the Currency (OCC) to custody crypto assets. In January 2021, the OCC cleared institutional digital asset platform Anchorage to function as a national bank.

I expect bitcoin and smaller cap altcoins to absolutely blow some minds in 2021, Hayner said. In addition, I'm expecting some major utility especially around stablecoins, NFT, innovative decentralized lending/trading models, oracles, and payment systems, he added, referring to a few niches of the crypto space that picked up interest in 2020, including non-fungible tokens (NFTs).

After bitcoins price run up to nearly $42,000 on January 8, the asset retraced down below $30,000 a few times amid sideways trading action over the past few weeks, according to TradingView data. I think we are seeing the very healthy retrace that many expected, Erik Finman told me in a January 26 message. Finman bought bitcoin back in 2011, later becoming a millionaire from his investment before the age of 20.

As much as people want bitcoin to just ride straight on up forever, there are always going to be bumps along the way, he said, referring to bitcoins recent price rally up past $40,000. Honestly, right now I think a lot of people have their eyes on meme-stocks like GameStop GME ! Stock shares for the popular video game store GameStop recently soared in price.

Over the next couple of weeks I expect the price to maintain, barring some relevant news event, Finman said of bitcoin. After that we will probably see new growth and a new all-time high once more, he added.

Bitcoin is a game of patience. Ultimately we must focus on adoption, on technological innovation, and on education. I understand it's hard for many to not watch the price all day when they have so much invested, but I believe many would find it rewarding to look away for a few minutes and keep their eyes on the prize.

Crypto still has its doubters, however, such as financial commentator Peter Schiff. In one of his recent tweets, Schiff, a known bitcoin skeptic, said the asset carries traits of scam types, including Ponzi schemes. Additionally, as per a January 11, 2021 tweet, billionaire Mark Cuban compared the scene in the crypto space to the dot-com bubble, which popped in the early 2000s, although he did say he expects some assets, such as btc and ethereum (ETH), to succeed in the long run.

Disclaimer: I actively trade cryptocurrencies, as well as hold varying amounts of BTC, ETH, LTC, ZEC, BCH, LINK, VGX, HBAR, XLM and ADA.

Visit link:

Crypto Has Entered Its Fourth Stage Of Adoption, Industry Exec Says - Forbes

Bitcoin Cash USD On Bearish Momentum: 6.82% Down In The Last 12 Hours – Via News Agency

Bitcoin Cash USD is currently on bearish momentum. At 20:05 EST on Friday, 29 January, Bitcoin Cash USD is at $404.53 and down by 6.82% in the last 12 hours.

Over the last six hours, Bitcoin Cash USDs higher value was $408.25 and the lower value was $403.77.

Over the last twelve hours, Bitcoin Cash USDs higher value was $432.13 and the lower value was $403.77.

About Bitcoin Cash USDs daily highs and lows, its 1.592% up from its trailing 24-hour low of $398.19 and 6.387% down from its trailing 24-hour high of $432.13.

In relation to Bitcoin Cash USDs yearly highs and lows, its 190.569% up from its 52-week low and 35.768% down from its 52-week high.

Bitcoin Cash USDs last day, last week, and last months average volatility was a positive 3.64%, a negative 1.07%, and a positive 1.54%, respectively.

Bitcoin Cash USDs last day, last week, and last months high and low average amplitude percentage was 6.86%, 8.60%, and 13.08%, respectively.

Skybridge's anthony scaramucci talks up new Bitcoin fund, crypto's 'exponential liftoff'. According to Business Insider on Wednesday, 27 January, "The SkyBridge Bitcoin Fund LP aims toprovidemass-affluent investors with an institutional-grade vehicle to gain exposure to Bitcoin. ", "SkyBridge initiated a position, valued at about $310 million earlier this month, in funds investing in Bitcoin during November and December 2020."

Cryptos young believers stoke a craze for Bitcoin penny stocks. According to Bloomberg Quint on Wednesday, 27 January, "Marathon Patent Group has computers in Montana and North Dakota, and recently announced it bought $150 million worth of Bitcoin for its Treasury reserves.", "And the fact that Bitcoin miners tend to be unprofitable or just barely in the black isnt much of a deterrent."

Bitcoin tumbles back below $30,000 as record momentum fades. According to Bloomberg Quint on Wednesday, 27 January, "Companies such as MicroStrategy Inc., Square Inc., and crypto miner Marathon Patent Group Inc. have all added some of their companys cash reserves into Bitcoin amid the rally."

Bitcoin might break down altogether, BIS head carstens warns. According to Bloomberg Quint on Wednesday, 27 January, "Investors must be cognizant that Bitcoin may well break down altogether," because the system becomes vulnerable to majority attacks as it gets close to its maximum supply of 21 million coins, BIS General Manager Agustin Carstens said in a speech for the Hoover Institution on Wednesday."

Microstrategy bond buyers rewarded with win-tie Bitcoin play. According to Bloomberg Quint on Thursday, 28 January, "When the enterprise software maker issued convertible debt in December with the intention of using the proceeds to add to its Bitcoin pile, the company opened a backdoor for bond investors to play the crypto craze.", "Even if Bitcoin goes down 30% to 40%, the company still has enough to pay this bond off easily."

Ray dalio calls Bitcoin one hell of an invention, considers it for new funds. According to Bloomberg Quint on Thursday, 28 January, "While Bitcoin has the potential to make investors "very rich" as well as "disrupt the existing monetary system," there are risks. ", "Dalio said he thinks of Bitcoin as a "long-duration option on a highly unknown future" and investing in it means recognizing the potential to lose about 80%."

Bitcoin investors May lose everything, central banker warns. According to Bloomberg Quint on Friday, 29 January, "On Friday, Bitcoin rallied above $35,000, with brokers attributing the move to Elon Musk mentioning the cryptocurrency in his bio page on Twitter.", "Still, Makhlouf doesnt see "financial stability issues at the moment arising from Bitcoin itself."

Bitcoin has leapt 17% after billionaire Elon Musk changes his twitter bio to '#Bitcoin'. According to Business Insider on Friday, 29 January, "Clearly the move is being cheered by the Bitcoin bulls," he said, and called the markets feverish trading around hot securities like Bitcoin and GameStop "risky."

Evolve files preliminary prospectus for Bitcoin ETF. According to Business Insider on Friday, 29 January, "TORONTO, Jan. 29, 2021 /CNW/ EvolveFunds Group Inc.("Evolve")is pleased to announce that it has filed a preliminary prospectus with the Canadian securities regulators for the Bitcoin ETF ("EBIT" or "the Fund"). ", "The Funds holdings will be priced based on the CME CF Bitcoin Reference Rate, a once-a-day benchmark index price for bitcoin denominated in U.S. dollars."

Read this article:

Bitcoin Cash USD On Bearish Momentum: 6.82% Down In The Last 12 Hours - Via News Agency

Bitcoin Cash USD On Bullish Momentum: 6.88% Up In The Last 6 Hours – Via News Agency

Bitcoin Cash USD is currently on bullish momentum. At 05:12 EST on Friday, 29 January, Bitcoin Cash USD is at $425.57 and up by 6.88% in the last 6 hours.

Over the last six hours, Bitcoin Cash USDs higher value was $425.57 and the lower value was $398.19.

Over the last twelve hours, Bitcoin Cash USDs higher value was $425.57 and the lower value was $398.19.

In relation to Bitcoin Cash USDs daily lows, its 9.065% up from its trailing 24-hour low of $390.20

Concerning Bitcoin Cash USDs yearly highs and lows, its 205.682% up from its 52-week low and 32.428% down from its 52-week high.

Bitcoin Cash USDs last day, last week, and last months average volatility was a positive 3.64%, a negative 1.07%, and a positive 1.54%, respectively.

Bitcoin Cash USDs last day, last week, and last months high and low average amplitude percentage was 6.86%, 8.60%, and 13.08%, respectively.

According to Business Insider on Tuesday, 26 January, "Of the two, the Roth version might have an edge, says Bogner, especially "if you are of the mindset that Bitcoin is going to explode" in price in the future. "

Bitcoin seen topping $50,000 long term as it vies with gold. According to Bloomberg Quint on Tuesday, 26 January, "Were talking about Bitcoin over the next three, five, 10 years slowly inching away at golds market capitalization," Vijay Ayyar, head of Asia Pacific with crypto exchange Luno in Singapore, said in an online question and answer session with Bloomberg Tuesday. ", "Predicting a price for Bitcoin is challenging but its likely to rise longer term as funds and family offices assign 0.5% or 1% of their portfolios to it, Long added."

Is Bitcoin mining worth the cost?. According to Bloomberg Quint on Tuesday, 26 January, "One Bitcoin transaction would generate the CO2 equivalent to 706,765 swipes of a Visa credit card, according to Digiconomists closely-followed index, albeit with none of the convenience of plastic. ", "Butits notable that the non-virtual side of Bitcoin buying -namely the energy consumption needed to mine and maintain it -gets far less attention. "

South Africa cracks down on Bitcoin after alleged ponzi scheme. According to Bloomberg Quint on Tuesday, 26 January, "South Africas finance-industry regulator wants more power to prosecute perpetrators of fraud and oversee dealing in cryptocurrencies after the collapse of a Bitcoin trader, alleged to be the countrys largest Ponzi scheme.", "MTI which in November claimed it had 260,000 members and 23,000 Bitcoin now worth about $740 million was placed in provisional liquidation last month after clients battled to withdraw funds. "

Skybridge's anthony scaramucci talks up new Bitcoin fund, crypto's 'exponential liftoff'. According to Business Insider on Wednesday, 27 January, "SkyBridge initiated a position, valued at about $310 million earlier this month, in funds investing in Bitcoin during November and December 2020.", "Its already happening," he said, citingBlackRock Inc.s adding Bitcoin futures as an eligible investment to two of its funds."

Cryptos young believers stoke a craze for Bitcoin penny stocks. According to Bloomberg Quint on Wednesday, 27 January, "And the fact that Bitcoin miners tend to be unprofitable or just barely in the black isnt much of a deterrent.", "Marathon Patent Group has computers in Montana and North Dakota, and recently announced it bought $150 million worth of Bitcoin for its Treasury reserves."

Bitcoin tumbles back below $30,000 as record momentum fades. According to Bloomberg Quint on Wednesday, 27 January, "Companies such as MicroStrategy Inc., Square Inc., and crypto miner Marathon Patent Group Inc. have all added some of their companys cash reserves into Bitcoin amid the rally."

Bitcoin might break down altogether, BIS head carstens warns. According to Bloomberg Quint on Wednesday, 27 January, "Investors must be cognizant that Bitcoin may well break down altogether," because the system becomes vulnerable to majority attacks as it gets close to its maximum supply of 21 million coins, BIS General Manager Agustin Carstens said in a speech for the Hoover Institution on Wednesday."

Microstrategy bond buyers rewarded with win-tie Bitcoin play. According to Bloomberg Quint on Thursday, 28 January, "So when the price of Bitcoin doubled, so did MicroStrategys shares, pushing the convertible deep into the money. ", "King estimates the value of the companys Bitcoin in the range of $800 million to $1.4 billion, assuming proceeds of the convertible offering were used to fund more buying. "

Ray dalio calls Bitcoin one hell of an invention, considers it for new funds. According to Bloomberg Quint on Thursday, 28 January, "Bridgewater Associates founder Ray Dalio said Bitcoin is "one hell of an invention" and hes considering cryptocurrencies as investments for new funds offering clients protection against the debasement of fiat money.", "While Bitcoin has the potential to make investors "very rich" as well as "disrupt the existing monetary system," there are risks. "

The rest is here:

Bitcoin Cash USD On Bullish Momentum: 6.88% Up In The Last 6 Hours - Via News Agency

USDT Transactions on Tron Surpassed Ethereum Tether Transactions Every Day in 2021 Altcoins Bitcoin News – Bitcoin News

During the last two months, tether transactions have spiked considerably. More recently, however, USDT transactions on the Tron network have outpaced the number of tether transfers on the Ethereum blockchain. Despite a whole lot more ERC20-based tethers in the wild, the minted stablecoin using the TRC20 standard has seen a much larger transaction count all year long.

Tether (USDT) is a dominant stablecoin and it is used on a great number of exchanges as the token is paired with nearly every digital asset that has a market value. USDT commands the third-largest market capitalization with a $24.9 billion valuation today.

During the last 24 hours market data shows that tether (USDT) has seen $17 billion in global trade volume. In the early days, tether was minted on the Omni Layer network but for the last four years, USDT tokens have migrated to other blockchains.

In 2021, USDT is issued on a myriad of chains including Ethereum, Tron, Bitcoin Cash, EOS, Liquid, Solana, and Algorand. A great majority of tethers are minted using Ethereums ERC20 standard, and these tokens have seen significant transaction counts in recent years.

However, this year has been a different story as the tether (USDT) transaction count stemming from the Tron network has been outperforming its ERC20 rival. Every single day in 2021, Tron-based tether (USDT) transaction counts (tx count) have been larger.

For instance, data from Coin Metrics shows the last count three days ago, TRC20 tethers saw 247,000 transactions while the ERC20 tethers saw 179,000 that day. Now even though TRC20 tethers have a larger tx count, the aggregated volume of ERC20 USDTs is still 2x more valuable in terms of settlement.

TRC20-based tethers have beat Ethereum-based tether tx counts week after week for the entire year. Of course, cryptocurrency proponents suspect that the migration from Ethereum to Tron as far as accelerated transactions is likely due to rising ETH network fees.

Fees on the Tron network are near non-existent and Coin Metrics data shows the chain processes 3.1 million transactions per day in comparison to BTCs 254,000+ transactions per day on January 24, 2021.

Ethereum transactions per day are currently over a million every 24 hours but the fees to transact with ether are much higher than the Tron networks negligible transfer costs.

At the time of publication, the median transaction fee on the Ethereum network according to data from bitinfocharts.com shows fees are currently around $4.80 per transaction. Theres been a number of days in 2021, where ETH transaction fees have jumped above the $5 range.

What do you think about the number of transactions stemming from tether on the Tron network exceeding the tether transactions on Ethereum? Let us know what you think in the comments section below.

Image Credits: Shutterstock, Pixabay, Wiki Commons, Coin Metrics, Bitinfocharts.com,

Disclaimer: This article is for informational purposes only. It is not a direct offer or solicitation of an offer to buy or sell, or a recommendation or endorsement of any products, services, or companies. Bitcoin.com does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.

Original post:

USDT Transactions on Tron Surpassed Ethereum Tether Transactions Every Day in 2021 Altcoins Bitcoin News - Bitcoin News

Bitcoin Jumps To Almost USD 38K, Ethereum, Altcoins Try To Follow – Cryptonews

Bitcoin price surged 20% after Elon Musk updated his Twitter bio with #Bitcoin. BTC broke the main USD 35,000 resistance and even climbed towards USD 38,000. It is currently (12:30 UTC) holding gains above USD 36,000 and it might soon revisit the USD 38,000 resistance.

Most major altcoins are trying to catch up. ETH/USD is up almost 10% and it broke the USD 1,400 resistance. XRP/USD spiked above USD 0.300, but there was no proper close.

Total market capitalization

The past few hours saw a massive increase in bitcoin price above the USD 34,500 and USD 35,000 resistance levels. BTC gained almost 20% and it even broke the USD 37,200 resistance. There was a spike almost to USD 38,000 before there was a correction. It is now trading well above USD 36,000. If the current trend remains intact, there are chances of a fresh run towards the USD 38,000 level.On the downside, the price might remain stable above USD 35,000 (the recent breakout zone). Any more losses could lead the price towards USD 34,200.

Ethereum price struggled to follow bitcoin, but it still managed to pop above the USD 1,350 and USD 1,375 resistance level. ETH traded above USD 1,400 and it is struggling to gain momentum above USD 1,425. A close above USD 1,425 might open the doors for a surge towards the USD 1,480 and USD 1,500 levels.On the downside, the USD 1,375 level is a decent support (a multi-touch zone). The next major support could be near the USD 1,350 level.

Bitcoin cash price settled above the USD 400 level and it surpassed the USD 425 resistance. BCH is now consolidating gains and it seems like it might rise towards the USD 440 and USD 450 resistance levels. If there is a downside correction, the USD 405 and USD 400 levels could act as strong supports.Litecoin (LTC) cleared the USD 138 and USD 140 resistance levels. LTC is showing positive signs above USD 140 and it could continue higher towards the USD 145 and USD 150 levels. Any more gains could open the doors for a push towards the USD 165 resistance level.XRP price surged over 10% and it even spiked above the USD 0.300 level. However, there was no close above USD 0.300. As a result, there was a fresh decline, but the price is stable above USD 0.280. It seems like the bulls might aim for another upside break above the USD 0.300 resistance level in the near term.

A few altcoins surged over 50%, including DOGE, WSB, SC, RVN, XVG, VGX, QNT, and FTM. Out of these, SC is gaining momentum above USD 0.008 and it is already up over 80%.

To sum up, bitcoin price is surging and it broke many important hurdles near USD 35,000 and USD 36,500. As a result, there are chances of a push towards USD 40,000 in the near term.

Read more from the original source:

Bitcoin Jumps To Almost USD 38K, Ethereum, Altcoins Try To Follow - Cryptonews

American Cancer Society Creates Its First Crypto Only Donation Fund News Bitcoin News – Bitcoin News

The American Cancer Society has set up a fund for crypto donations so the nonprofit can raise at least $1 million by early 2021. Together with The Giving Block, the U.S.-based voluntary health organization expects to collect funds via several cryptocurrencies.

According to the announcement, the cancer crypto fund seeks to provide funding to ongoing research initiatives. The move happens within the context of a strong decrease in donations over 2020 amid the COVID-19 pandemic.

The American Cancer Society says the donations flow plunged 50% in the last year the lowest number in this century. They commented on the motivations behind setting up a crypto fund:

The crypto communitys contributions will help re-establish crucial research funding for new discoveries and better treatments to save the lives of family and friends.

Per the official crypto fund website, donations can be made in bitcoin (BTC), bitcoin cash (BCH), ether (ETH), litecoin (LTC), zcash (ZEC), gemini dollar (GUSD), basic attention token (BAT) and chainlink (LINK).

The nonprofit health organization said that the first donor who contributes $250,000 or more would have the chance to name the fund. On the other side, donors with over $10,000 contributions will appear on the crypto funds wall of honor.

Jeff Klass, the interim chief digital officer at the American Cancer Society, commented on the announcement:

We want as many people to join us in our mission as possible. To do that, we need to ensure people can give to the fight against cancer when, where, and how they choose. We appreciate The Giving Blocks work to help make this possible.

Moreover, the American Cancer Society recognizes the emergency of cryptocurrency, specifically the impact cancer has across the crypto community.

Pat Duffy, a co-founder of The Giving Block, said the following about cryptocurrencies relevance in this kind of initiatives:

I believe cryptocurrency will play a pivotal role in curing cancer. () With bitcoin hitting a new all-time high, the creation of this new fund opens the door for the booming crypto market to save lives.

What do you think about this crypto cancer fund? Let us know in the comments section below.

Image Credits: Shutterstock, Pixabay, Wiki Commons, American Cancer Society

Disclaimer: This article is for informational purposes only. It is not a direct offer or solicitation of an offer to buy or sell, or a recommendation or endorsement of any products, services, or companies. Bitcoin.com does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.

Continue reading here:

American Cancer Society Creates Its First Crypto Only Donation Fund News Bitcoin News - Bitcoin News

Bitcoin Cash USD On Bullish Momentum: 5.93% Up In The Last 6 Hours – Via News Agency

Bitcoin Cash USD is currently on bullish momentum. At 20:07 EST on Sunday, 24 January, Bitcoin Cash USD is at $451.97 and up by 5.93% in the last 6 hours.

Over the last six hours, Bitcoin Cash USDs higher value was $451.97 and the lower value was $426.67.

Over the last twelve hours, Bitcoin Cash USDs higher value was $451.97 and the lower value was $426.67.

Concerning Bitcoin Cash USDs daily lows, its 5.93% up from its trailing 24-hour low of $426.67

About Bitcoin Cash USDs yearly highs and lows, its 224.644% up from its 52-week low and 28.236% down from its 52-week high.

Bitcoin Cash USDs last day, last week, and last months average volatility was a negative 2.32%, a negative 2.04%, and a positive 2.49%, respectively.

Bitcoin Cash USDs last day, last week, and last months high and low average amplitude percentage was 5.65%, 10.78%, and 13.49%, respectively.

Why this analyst is cautioning Bitcoin investors to have A 'very strong stomach' amid plunge. According to Business Insider on Friday, 22 January, "Price Action: Bitcoin traded 11.3% lower at $30,712.41 at press time on Thursday.", "Why It Matters: Bitcoin has seen a major correction in the last two weeks after a dizzying rally that started in July last year saw it cross $40,000 from trading below the $10,000 level."

Iran blames 1600 Bitcoin processing centers for massive blackouts in tehran and other cities. According to Business Insider on Saturday, 23 January, "According to local media, state-owned electricity firm Tavanir shut down a large Iranian-Chinese Bitcoin farm amid the power outages.", "Mohammad Hassan Motavalizadeh, the head of Tavanir, said that 45,000 illegal Bitcoin machines cheaply consuming 95MWh of electricity had been confiscated by the police, it also added."

According to Business Insider on Saturday, 23 January, "And this was a Bitcoin OTC name that has been consolidating for months.", "For the Bitcoin theme, Hasson had identified over 10 stocks on the NASDAQ as well as over-the-counter stocks to watch and monitor everyday."

Bitcoin outlook: my mantra for 2021 can make you money. According to Business Insider on Saturday, 23 January, "The post Bitcoin Outlook: My Mantra for 2021 Can Make You Money appeared first on InvestorPlace."

Visit link:

Bitcoin Cash USD On Bullish Momentum: 5.93% Up In The Last 6 Hours - Via News Agency

Gemini research reveals 2 in 5 crypto investors in the UK are women – PR Newswire UK

National survey finds 13.5% of UK population are current or previous investors in digital assets, up 152% from previous studies

LONDON, Jan. 29, 2021 /PRNewswire/ -- New data from Gemini, the cryptocurrency exchange and custodian, presents the demographic profile of existing and potential crypto investors in the UK market. The results of a nationally representative survey of 2,000 respondents challenge certain long-held stereotypes about consumer engagement with digital assets, while reinforcing other past research.

The most significant trends are outlined in the Gemini State of Crypto Report 2021. The Report builds a picture of how factors such as gender, age, family status, educational attainment, income, location, technology usage, and the COVID-19 pandemic impact crypto investment.

Key findings include:

Blair Halliday, Head of UK at Gemini, said, "This new data demonstrates an increasingly diverse base engaging with crypto and indicates how the market is likely to evolve over the longer term. As the industry develops, there are more safe, secure, and regulated platforms available for trading and investing, meaning crypto has never been more accessible. We expect the reach of crypto to widen further, particularly as the 9.0% who are interested in crypto enter the market. The sector has a huge opportunity to educate the 38.7% of respondents who either do not know anything at all about crypto, or do not know enough to invest."

For more insights, download the full report athttps://www.gemini.com/state-of-uk-crypto

About Gemini Europe

Gemini Europe has offices in London and Dublin and is registered as an e-money institution in the UK by the Financial Conduct Authority. Gemini Europe provides individuals and institutions with trusted products and tools to buy, sell, and store cryptocurrencies like Bitcoin, Bitcoin Cash, Basic Attention Token (BAT), Dai, Ethereum, Litecoin, ChainLink (LINK) and Orchid (OXT).

SOURCE Gemini

Go here to see the original:

Gemini research reveals 2 in 5 crypto investors in the UK are women - PR Newswire UK

How to buy bitcoin in a IRA: Rules, benefits, risks, and where to buy – Business Insider – Business Insider

Not a day goes by without bitcoin being in the news. And given the cryptocurrency's phenomenal price rise, from zero to approximately $32,000 in a little over a decade, you like many other individual investors may be tempted to buy in. But how?

Actually, you can invest in finance's newest asset via one of its most familiar vehicles: the IRA. Yes, you can buy bitcoin for a good old individual retirement account.

Cue the excitement? Maybe. In many ways, bitcoin investments are well-suited to an IRA. But, as with any investment strategy, there are pros and cons to consider.

Bitcoin is a type of cryptocurrency (sometimes called a digital or virtual currency) the oldest, and most popular of the dozen varieties available for trading and investment. So a bitcoin IRA is a type of investment retirement account that includes bitcoin within its portfolio.

Although these accounts may carry the name "bitcoin," they also allow you to invest in other cryptocurrencies, like ethereum, litecoin, and bitcoin cash.

You can't put bitcoin into a pre-existing, regular IRA that holds your stocks, bonds, ETFs, or mutual funds. Instead, you have to set up a special one, technically known as a self-directed IRA (SDIRA). The reason: The Internal Revenue Service (IRS) deems cryptocurrencies like bitcoin a type of property, which is off-limits to regular IRAs.

"A self-directed IRA has a little bit looser IRS rules, so you can hold things like property," or other alternative investments, confirms Victoria Bogner, a certified financial planner and chief executive officer of McDaniel Knutson.

In some ways, bitcoin IRAs work like regular IRAs. While you can set one up with any amount of funds, they have annual contribution limits set by the IRS: You can only contribute $6,000 a year for 2020 and 2021 (or $7,000 a year if you're age 50 or older). Any returns, income, or gains generated by the investments within them grow tax-free.

You can also establish a bitcoin IRA as either a traditional account (for which contributions are tax-deductible, and funds taxed upon withdrawal) or a Roth account (no tax break on contributions, but distributions are tax-free).

Of the two, the Roth version might have an edge, says Bogner, especially "if you are of the mindset that Bitcoin is going to explode" in price in the future. Roth IRAs are preferred by investors who project they'll be in a higher tax bracket when they retire and start withdrawing money from the account. Since the Roth is funded with after-tax dollars, they won't owe anything on their bitcoin gains even if the currency has gone up 10 or 20 times.

Bitcoin IRAs do operate differently in a few ways, though.

As the "self-directed" implies, these IRAs are directly managed by the account holder (as opposed to a financial advisor or money manager). And your regular brokerage, bank, or investment app probably doesn't handle them. Self-directed IRAs are only available through firms that specialize in the type of asset you're interested in.

So, to open a bitcoin IRA, you'd work with special custodians that can hold and deal in cryptocurrency. Some custodians require an application, walking you through the process. If you move forward, you can then fund these accounts via a rollover of funds from an existing IRA or another tax-advantaged account, or contribute new funds.

Some of the better-known, established companies that let you set up bitcoin IRAs include:

This is still a young field, and information on a firm may be hard to come by. Frankly, some are little more than sales platforms. So, no matter which custodian you're considering, be sure to do your due diligence on it.

Visit its website or call its customer service line to confirm and compare its fee structure, operations. Ask how your bitcoins will be stored, exactly, and about security procedures and measures you don't want your account holdings vulnerable to hackers.

There are plenty of positives to consider with bitcoin IRAs.

No investment is without risk. Potential issues also exist with bitcoin IRAs.

Quick tip: An IRA custodian should never promise your account is protected against losses due to a drop in your holdings' price or value. It's not. Protection against literal loss, due to theft or the firm going bankrupt, possibly. Protection from investment loss, never.

Bitcoin IRAs can offer an opportunity for investors who believe in the crypto's future, but who want some tax savings along with their gains. Plus, the ease of dealing with a familiar type of account.

But there can be higher fees and account minimums when compared to other IRAs, so determine whether the trade-off is appropriate for you. Bear in mind that there are other ways to hold bitcoin, in regular accounts on crypto trading platforms like Coinbase and Binance US.

If you decide to open a bitcoin IRA, choose a custodian carefully. And only commit to bitcoin an amount that you can afford to lose, and think long term. Says Bogner: "Twenty years later, hopefully it's worth more than what you put in."

Continue reading here:

How to buy bitcoin in a IRA: Rules, benefits, risks, and where to buy - Business Insider - Business Insider

Bitcoin Holds Steady Above USD 30K, Ethereum and Altcoins Gain Traction – Cryptonews

Bitcoin price is stable above USD 30,500 and USD 31,000. BTC is currently (13:00 UTC) attempting an upside break above USD 31,800 and USD 32,000. A close above USD 32,000 could open the doors for a larger increase in the coming sessions.

Besides, most major altcoins are showing signs of a fresh increase, including ethereum, EOS, XRP, XLM, LINK, BNB, OMG, NEO, TRX, bitcoin cash, DOT, litecoin, and ADA. ETH/USD is back above USD 1,300 and it seems like the bulls are aiming for a break above USD 1,350. XRP/USD is trading above USD 0.255 and it is likely to climb towards USD 0.285 or USD 0.292.

Total market capitalization

In the past two sessions, bitcoin price traded in a range above the USD 31,000 support zone. BTC is slowly moving higher towards the USD 32,000 resistance level. The next key resistance is near the USD 32,400 level, above which the bulls are likely to target a 5%-8% move in the near term.

If there is no clear break above USD 32,000 and USD 32,400, there are chances of a fresh decline. An initial support is near the USD 31,000 level. The main support is now forming near the USD 30,000 level, below which the price could dive towards USD 29,200.

Ethereum price is slowly gaining bullish momentum above USD 1,280. ETH even surpassed the USD 1,300 level and it is likely to continue higher. The next key resistance sits near USD 1,350. A close above USD 1,350 may possibly spark a sharp rally in the coming sessions.

If ETH fails to stay above USD 1,300, it could correct lower. An initial support is near USD 1,285. The key support for the current wave is near the USD 1,250 level.

Bitcoin cash price is struggling to clear the USD 400 and USD 405 resistance levels. If BCH settles above USD 405, there could be a slow and steady rise towards the USD 432 and USD 435 levels. On the downside, the USD 385 level is a short-term support, followed by the USD 370 level.

Litecoin (LTC) is up 4% and it is testing the USD 130 level. An immediate resistance is near USD 132. If there are more upsides, the bulls might aim a test of the USD 140 resistance level. On the downside, the USD 125 level is a decent support, followed by the USD 118 zone.

XRP price remained stable and it recovered above the USD 0.255 level. If it clears the USD 0.265 resistance, there could be a drift towards the USD 0.285 and USD 0.292 resistance levels. The main hurdle on the upside is still near the USD 0.300 level.

In the past few hours, many altcoins gained over 10%, including DOGE, 1INCH, LUNA, EGLD, CHSB, ZEN, RUNE, QNT, ALPHA, KSM, SC, ATOM, LINK, and FTM. Out of these, DOGE grabbed the market's attention with a massive rally above USD 0.014.

To sum up, the bitcoin price is stable above USD 31,000, but it must clear the USD 32,000 and USD 32,500 resistance levels. If not, there is a risk of a fresh drop to USD 30,000._____

Go here to read the rest:

Bitcoin Holds Steady Above USD 30K, Ethereum and Altcoins Gain Traction - Cryptonews

US Court Sentences ICO Fraudster to 6 Months in Jail: Orders the Accused to Pay Over $4 Million in Restitution Regulation – Bitcoin News

A U.S. court has sentenced Jerry Ji Guo, a resident of San Francisco, to an effective six months in prison for his role in a fraudulent initial coin offering (ICO). In addition to the prison term, the court ordered Guo to pay over $4 million in restitution. Further, Guo will also cooperate with the government in the identification and return of the stolen property.

In a statement, the United States Department of Justice (DOJ) says Guo, who pleaded guilty on August 26, 2019, had presented himself as an ICO consultant and promised his clients he would perform marketing and publicity services. However, instead of fulfilling his promises, Guo embezzled the clients cash and cryptocurrency.

As court documents show, a U.S. grand jury initially indicted Guo on November 15, 2018, charging him with eight counts of wire fraud, in violation of 18 U.S.C. 1343. However, the statement says Guo only pleaded guilty to one count while the rest of the charges were dismissed.

Meanwhile, in his remarks, the United States Attorney David L. Anderson, suggests that the countrys law enforcement has now caught up with crypto criminals. He says:

Some criminals believe mistakenly that cryptocurrency is beyond the reach of law enforcement. This case shows we can use criminal forfeiture to compensate fraud victims even when cryptocurrency is used in the fraud.

According to the DOJ statement, after Guos indictment, the government went on to obtain a stipulated application for a preliminary order of forfeiture on November 14, 2019. Further, the government also obtained warrants to seize the stolen cash and cryptocurrency while a final order of forfeiture against the stolen property was obtained on February 26, 2020.

In the meantime, the DOJ statement goes on to say that the Money Laundering and Asset Recovery Section, a component of the DOJs Criminal Division will use the victim restoration process to return stolen property to victims.

Do you think the DOJ will enjoy similar success in other ICO fraud cases? Tell us what you think in the comments section below.

Image Credits: Shutterstock, Pixabay, Wiki Commons

Disclaimer: This article is for informational purposes only. It is not a direct offer or solicitation of an offer to buy or sell, or a recommendation or endorsement of any products, services, or companies. Bitcoin.com does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.

View original post here:

US Court Sentences ICO Fraudster to 6 Months in Jail: Orders the Accused to Pay Over $4 Million in Restitution Regulation - Bitcoin News

Bitcoin On Bearish Momentum: 11.62% Down In The Last 12 Hours – Via News Agency

Bitcoin is currently on bearish momentum. At 20:03 EST on Friday, 29 January, Bitcoin is at $34,357.20 and down by 11.62% in the last 12 hours.

Over the last six hours, Bitcoins higher value was $34,688.99 and the lower value was $33,967.74.

Over the last twelve hours, Bitcoins higher value was $38,347.86 and the lower value was $33,967.74.

About Bitcoins daily highs and lows, its 6.549% up from its trailing 24-hour low of $32,245.49 and 10.406% down from its trailing 24-hour high of $38,347.86.

Regarding Bitcoins yearly highs and lows, its 736.556% up from its 52-week low and 18.093% down from its 52-week high.

Bitcoins last day, last week, and last months average volatility was 4.00%, 0.38%, and 0.26%, respectively.

Bitcoins last day, last week, and last months high and low average amplitude percentage was 6.22%, 8.55%, and 10.22%, respectively.

Skybridge's anthony scaramucci talks up new Bitcoin fund, crypto's 'exponential liftoff'. According to Business Insider on Wednesday, 27 January, "Its already happening," he said, citingBlackRock Inc.s adding Bitcoin futures as an eligible investment to two of its funds.", "The SkyBridge Bitcoin Fund LP aims toprovidemass-affluent investors with an institutional-grade vehicle to gain exposure to Bitcoin. "

Cryptos young believers stoke a craze for Bitcoin penny stocks. According to Bloomberg Quint on Wednesday, 27 January, "And the fact that Bitcoin miners tend to be unprofitable or just barely in the black isnt much of a deterrent.", "While Bitcoin prices tend to move in the realm of 5% to 10% a day, its not uncommon for the mining stocks to swing 20%. "

Bitcoin tumbles back below $30,000 as record momentum fades. According to Bloomberg Quint on Wednesday, 27 January, "Companies such as MicroStrategy Inc., Square Inc., and crypto miner Marathon Patent Group Inc. have all added some of their companys cash reserves into Bitcoin amid the rally."

Bitcoin might break down altogether, BIS head carstens warns. According to Bloomberg Quint on Wednesday, 27 January, "Investors must be cognizant that Bitcoin may well break down altogether," because the system becomes vulnerable to majority attacks as it gets close to its maximum supply of 21 million coins, BIS General Manager Agustin Carstens said in a speech for the Hoover Institution on Wednesday."

Microstrategy bond buyers rewarded with win-tie Bitcoin play. According to Bloomberg Quint on Thursday, 28 January, "The founder had become a big bull on Bitcoin and invested its very large cash pile in it," he said. ", "King estimates the value of the companys Bitcoin in the range of $800 million to $1.4 billion, assuming proceeds of the convertible offering were used to fund more buying. "

Ray dalio calls Bitcoin one hell of an invention, considers it for new funds. According to Bloomberg Quint on Thursday, 28 January, "Dalio said he thinks of Bitcoin as a "long-duration option on a highly unknown future" and investing in it means recognizing the potential to lose about 80%.", "Bridgewater Associates founder Ray Dalio said Bitcoin is "one hell of an invention" and hes considering cryptocurrencies as investments for new funds offering clients protection against the debasement of fiat money."

Bitcoin investors May lose everything, central banker warns. According to Bloomberg Quint on Friday, 29 January, "On Friday, Bitcoin rallied above $35,000, with brokers attributing the move to Elon Musk mentioning the cryptocurrency in his bio page on Twitter.", "Still, Makhlouf doesnt see "financial stability issues at the moment arising from Bitcoin itself."

Bitcoin has leapt 17% after billionaire Elon Musk changes his twitter bio to '#Bitcoin'. According to Business Insider on Friday, 29 January, "Clearly the move is being cheered by the Bitcoin bulls," he said, and called the markets feverish trading around hot securities like Bitcoin and GameStop "risky."

Evolve files preliminary prospectus for Bitcoin ETF. According to Business Insider on Friday, 29 January, "TORONTO, Jan. 29, 2021 /CNW/ EvolveFunds Group Inc.("Evolve")is pleased to announce that it has filed a preliminary prospectus with the Canadian securities regulators for the Bitcoin ETF ("EBIT" or "the Fund"). ", "The Funds holdings will be priced based on the CME CF Bitcoin Reference Rate, a once-a-day benchmark index price for bitcoin denominated in U.S. dollars."

Continued here:

Bitcoin On Bearish Momentum: 11.62% Down In The Last 12 Hours - Via News Agency

How to Build Narrative Power and Co-Create a Just Future – Resilience

This article is based on content fromSeeds, Stories, Strategies: A Climate Justice Web Series, which took place in July 2020 as part of a collaboration between the Center for Cultural Power, Center for Story-Based Strategy, Movement Generation, Movement Strategy Center, and Race Forward.

Before we can set to work tearing down old systems and building up better ones, we first have to imagine where we want to go. Material liberation requires a mental liberation, and imagination is a powerful tool to free ourselves from repressive cultural narratives and social power structures.

Heres an exercise you can try for yourself: Imagine youre in the year 2030 looking back on 2020 and remembering societys response to the twin crises of the pandemic and systemic racism. Then describe what happened by starting with, Remember when and follow it with a sentence about a challenging moment from 2020. For the next step, imagine how these issues were overcome, again using the Remember when framing. Some examples include: how people demanded change, communities organized and protested, politicians enacted policy solutions to climate crises, and companies incorporated social and environmental impact into their bottom lines.

Once youve started imagining, you can begin building a narrative strategy. The framing of a narrative is an intentional and strategic choice, determining who is in and who is out of the stories we tell and the approaches we propose. It is important for social movements to introduce their own framing because if we dont tell our own stories, others will create them for us.

For a pertinent example of the importance of framing, we can look at media coverage of Hurricane Katrina and its aftermath, when articles labeled individuals as looters or survivors depending on race. In this way, framing provides a casting of characters and impacts how audiences name movements and their actions. A more concrete organizational case is the Dakota Access Pipeline protests, which made an explicit choice to move away from a narrow anti-pipeline focus toward the more general environmental justice and water is life narrative.

ByPax Ahimsa Gethenvia Wikipedia (CC BY-SA 4.0)

Leveraging the importance of framing enables us to reach beyond using magic words in a vacuum, and focus instead on so-called points of intervention. This, in turn, gives us a framework for understanding where to take action in a system we are trying to change, and is necessary in recognizing the structure of our problem rather than just analyzing a single issue. Points of intervention help us determine how to be strategic in deploying our stories. They provide insight about how and where we can challenge the dominant narratives that shape social mythologies, such as the bootstrap myth of capitalist ethics. More practically, they are points of vulnerabilities where dominant narratives are already weak.

At points of intervention, its useful to show stories rather than tell them, and to use storytelling to disrupt and reframe existing narratives. Dominant narratives can be further broken down in terms of their points of production, points of decision, points of destruction, points of consumption, and points of assumption and we can use our analysis to shape strategies for optimal effect.

Humans are narrative driven, and the currency of narrative is meaning, not facts. Take the Big Dipper, a stellar constellation that is not actually shaped like a pan but nonetheless assigned meaning by humans, making it useful for navigation and cultural memetics. Activists often focus on facts, but ultimately it is our human connection with meaning that moves people.

Narrative power is the power to dictate norms and values in society. This includes the ability to shape whats possible and determine whats politically realistic, and even to stretch beyond the possible and establish what is inevitable.

If a story is an individual star, a narrative is a constellation an aggregate of stories that show us a pattern. To continue the analogy, culture is like a galaxy, featuring a wide range of complexity and movement and also the context that allows us to make sense of our stories. The purpose of narrative and cultural strategy for justice is to build power for impacted communities. While social movements generate narratives, the work of cultural strategists is to make these narratives sustainable for long-term cultural change.

The Big Dipper byjpstanleyvia Flickr (CC BY-NC-SA 2.0)

Narratives and culture are epistemic in that they frame how we know things. The real praxis of narrative and cultural strategy work therefore involves teaming up with cultural producers in order to re-shape perceptions of reality. This brings us back full circle to the power of radical imagination: narrative and culture are essential to shifting material conditions.

To do so, we have to strategize at each level of story, narrative, and culture. A good example is the #MeToo movement, which can be thought of as an aggregate of narratives coupled with a social proliferation mechanism (the internet) that enables pressure from social action over multiple spheres of society including politics, law, media, and entertainment.

The true power of storytelling lies in our ability to bring our audience into a shared vision of change. As Antoine de Saint Exupry wrote: If you want to build a ship, dont drum up people to collect wood and dont assign them tasks and work, but rather teach them to long for the endless immensity of the sea.

Crafting powerful stories requires a solid understanding of the common elements of story-telling: conflict, characters, imagery, foreshadowing, and underlying assumptions. These elements can be used to show how power is upheld or how countervailing power can be built up.

These fundamental elements can be aligned to construct a narrative pyramid composed of a message, a story, a narrative, and a deep narrative. While messages are ephemeral, humans connect and remember stories and narrative thanks to the basic elements of story-building. Stories make sense through the context of a narrative which ultimately proposes responsibility and action, bringing our audience into a shared vision sustaining a deeper narrative to change underlying assumptions.

Find out more about thePost Growth Institute on our website.

See original here:

How to Build Narrative Power and Co-Create a Just Future - Resilience

ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -…

IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and Pre-Clinical Research as part of ClearPoints Biologics and Drug Delivery team on March 1, 2021. Dr. Salegio brings over 19 years of experience in translational neuroscience with direct pre-clinical central nervous system (CNS) expertise in the delivery of therapeutics to the brain and spinal cord, including over 16 years of gene therapy experience working with adeno-associated viral vectors (AAV).

ClearPoint Neuros Biologics and Drug Delivery team was established in 2020 to provide turn-key medical device innovation, therapy delivery development and clinical services customized for both pharmaceutical and academic partners working on gene and stem cell therapies to the brain. This team also offers comprehensive services to help its partners navigate existing regulatory guidance and stay abreast of anticipated changes to guidance that will inevitably come.

Our current and prospective partners working on gene and stem cell therapies have an enormous unmet need for pre-clinical support, commented Jeremy Stigall, Vice President, Biologics & Drug Delivery Development. Ernestos extensive pre-clinical expertise in the intraparenchymal administration of therapeutics under image-guidance, as well into cerebrospinal fluid (CSF), will allow ClearPoint to add crucial translational consulting services for our biologics partners. When we establish relationships with pharmaceutical partners well before the clinic, ClearPoint products and services can be incorporated throughout the entire development process, delivering consistent, predictable performance, and providing government agencies assurance that the navigation and delivery platform will remain constant from bench-to-bedside. We aim to become their comprehensive medical device partner, allowing them to focus on more traditional pharmaceutical challenges, while ClearPoint delivers state-of-the-art medical device and therapy delivery.

I am thrilled to become a member of the ClearPoint team, commented Dr. Salegio. After spending almost two decades focusing on translational research, image-guided delivery protocols, complex surgical procedures and in the development of CNS therapies, I am delighted to drive the expansion of ClearPoints capabilities. I am eager to leverage their current pre-clinical and clinical portfolio, as well as to their pipeline of innovative tools on the horizon, to provide customized solutions to current and future ClearPoint pharmaceutical partners.

About ClearPoint Neuro

ClearPoint Neuros mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Companys current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States and the EU. The Companys SmartFlow cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Companys field-based clinical specialist team which offers support and services for our partners. For more information, please visit http://www.clearpointneuro.com.

Forward-Looking Statements

Statements herein concerning the Companys plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Companys ClearPoint Neuro Navigation System products; the Companys ability to market, commercialize and achieve broader market acceptance for the Companys ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Companys cash resources. More detailed information on these and additional factors that could affect the Companys actual results are described in the Risk Factors section of the Companys Annual Report on Form 10-K for the year ended December 31, 2019, and the Companys Quarterly Report on Form 10-Q for the three months ended September 30, 2020, both of which have been filed with the Securities and Exchange Commission, and the Companys Annual Report on Form 10-K for the year ended December 31 2020, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2021.

Go here to see the original:

ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -...

Cell Therapy Market 2020 Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2025 KSU | The Sentinel Newspaper – KSU | The…

Global Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 released at MarketQuest.biz offers widespread assessment and emphasizes fundamental synopsis of the global industry, embracing categorizations, applications, explanations, and manufacturing chain structure. The report discloses the overview of the market and then analyzes the market size (in terms of value and volume) and forecast by type, application/end-user, and region. The report contains a market competitive landscape and company profile between vendors, as well as market price analysis and value chain characteristics. The global Cell Therapy market research report sheds light on the assessment of its diverse segments and main geographies.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitors Analysis:

The competitive landscape offers a corresponding detailed analysis of the major vendors/manufacturers in the global Cell Therapy market. The report examined the key drivers influencing market growth, opportunities, challenges, and the risks faced by key players and the market. It also assesses key emerging trends and their impact on present and future development. This research study assists users to evaluate company shares analysis, emerging product lines, pricing strategies, innovation possibilities, and much more.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/26120

The competitive terrain of the market, as per the report, is inclusive of numerous companies such as: Gilead Sciences, Beike Biotechnology, Vericel Corporation, Novartis, JCR Pharmaceuticals, Osiris, Guanhao Biotech, Fujifilm Cellular Dynamics, Vcanbio, Golden Meditech

In market segmentation by types, the report covers: Stem Cell, Non-Stem Cell

In market segmentation by applications, the report covers the following uses: Hospital, Clinic

Regionally, this report focuses on several key regions: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia, Italy, Spain, Benelux, Nordic), Asia (China, Japan, Korea, India, Southeast Asia, Australia and Taiwan), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey)

The report also specifies the computed expected CAGR of the market estimated on the basis of the existing and previous records concerning the global Cell Therapy market. Besides, the report covers various tactics to discover the weaknesses, opportunities, risks, and strengths having the potential to impact the global market expansion. The report helps to evaluate and understand the market and its applications on a global level.

Key Deliverables In The Study:

ACCESS FULL REPORT: https://www.marketquest.biz/report/26120/global-cell-therapy-market-2020-by-company-type-and-application-forecast-to-2025

Moreover, the report is assumed as the keeping source for market profitability in the research that is expected to raise the business potentials. In addition, the global Cell Therapy market report provides innovative strategies towards the SWOT study, examination of the industrial development. Also, the report delivers breakdown and data triangulation, consumer needs/customer preference change, research findings, market size estimation, and data source.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketquest.bizWeb: http://www.marketquest.biz

More:

Cell Therapy Market 2020 Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2025 KSU | The Sentinel Newspaper - KSU | The...

Stem Cell Therapy Market 2021 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2026 NeighborWebSJ – NeighborWebSJ

This report of the global , Stem Cell Therapy Market systematically focuses on various factors such as current and past situations, developments, noteworthy business skills, preferences, and player strategies directly chosen by key market players to ensure stable revenue generation and long-term stability. Sure probability. With this report, research analysts and industry experts also aim to provide ample light on additional essential determinants such as scrutiny review and assessment of opportunities for analysis, as well as the threats and challenges that continue to curb the growth spike in the Stem Cell Therapy Market. The report provides a useful overview highlighting various aspects that encourage conservative business decisions in the Stem Cell Therapys market.

The market scope segment provides revenue to the electronic equipment market, predicting significant growth and future of the market. Stem Cell Therapy Market separation breaks down the major sub-areas that make up the market. The weekly segmentation section provides the biological market size. The modest background explains the competitive nature of the market, the market dividends and the description of the major players. Significant financial transactions that have shaped the market over the past few years are recognized.

Request For Sample PDF @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

Various workable inputs on ongoing market competition, growing intensity and relevant details about new product and technology development are included in the Stem Cell Therapy Market report. Additional details on M&A, commercial agreements and technology enhancements are also incorporated in the report. This section of the report draws attention towards competition analysis of the highlighted players and prominent vendors. Each of the mentioned players company and business overview with details on revenue generation, objectives and profit margin have been duly addressed in the report to encourage thoughtful business decisions amongst market aspirants as well as established players alike.

The report provides ample light on several market components such as key trends, ongoing challenges, as well as barriers and threats that significantly limit the growth of the global Stem Cell Therapy Market. This carefully written research report takes into account all the dominant regional and country-specific developments in the global Stem Cell Therapy Market. This report mainly focuses on key developments in North and South America, Europe, APAC and MEA regions

Complete Summary with TOC Available @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

Global Stem Cell Therapy Market 2020-26: Competitive Landscape Analytical Review

Compilation of this latest research report drives readers to have ongoing market developments, including paralyzing business and industrial development in numerous ways, including unprecedented advances such as the COVID-19 outbreak. The report is structured to highlight effective clues to growth-oriented business decisions, enabling manufacturers and stakeholders in the Stem Cell Therapy Market to come up with growth-friendly strategies and tactics.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Systematic Guide to Report Investment

The report presents market size dimensions based on value and volume estimationsThe report demonstrates details on major dynamic alterations initiating growth diversionsThe report illustrates a touchpoint description of emerging segments and lucrative regional growth spots

What to expect from the Stem Cell Therapy Market report

1. The report investigates and makes the best forecasts related to market size and value estimation.2. A thorough evaluation to investigate material source and downstream purchasing development is reflected in the report.3. This report aims to characterize and segment the Stem Cell Therapy Market as a whole for the best reader understanding.4. Detailed references to buyer needs, barrier analysis and opportunity assessment are also taking root.

Market Report Highlights:

Chapter1. Executive SummaryChapter2. Research MethodologyChapter3. Stem Cell Therapy Market OutlookChapter4. Global Stem Cell Therapy Market Overview, By TypeChapter5. Global Stem Cell Therapy Market Overview, By ApplicationChapter6. Global Stem Cell Therapy Market Overview, By RegionChapter7. Company Profiles

Ask our Expert if You Have a Query @: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 210-667-2421/ +91 9665341414

See the rest here:

Stem Cell Therapy Market 2021 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2026 NeighborWebSJ - NeighborWebSJ

Researchers use patients’ cells to test gene therapy for rare eye disease – National Institutes of Health

News Release

Thursday, January 28, 2021

Approach could provide new path for difficult-to-treat forms of Leber congenital amaurosis.

Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood. A form of Leber congenital amaurosis, the disease is caused by autosomal-dominant mutations in the CRX gene, which are challenging to treat with gene therapy. The scientists tested their approach using lab-made retinal tissues built from patient cells, called retinal organoids. This approach, which involved adding copies of the normal gene under its native control mechanism, partially restored CRX function. The study report appears today in Stem Cell Reports. NEI is part of the National Institutes of Health.

Our treatment approach, which adds more copies of the normal gene, could potentially treat autosomal-dominant LCA caused by a variety of mutations, said Anand Swaroop, Ph.D., chief of the NEI Neurobiology, Neurodegeneration and Repair Laboratory and senior author of the report.

The U.S. Food and Drug Administration approved Luxturna in 2017 for the treatment of LCA patients with mutations in a gene called RPE65. Although hailed as a major advance in gene therapy, Luxturna is ineffective against other forms of LCA, including those caused by autosomal-dominant mutations in CRX.

The CRX gene encodes a protein (also called CRX) that binds to DNA and instructs the retinas photoreceptors to make light-sensitive pigments called opsins. Without functional CRX protein, photoreceptors lose their ability to detect light and eventually die.

Disorders like autosomal-dominant LCA are tricky to treat with gene therapy, because adding more of the normal gene does not always restore function. People with autosomal-dominant mutations still have one normal copy of the gene, but the mutant version of the protein interferes with the normal protein. Sometimes, instead of restoring normal function, simply adding more of the normal protein can enhance the disease in unpredictable ways.

To explore how gene augmentation adding copies of the normal gene would affect autosomal-dominant LCA, Swaroops team, developed retinal organoids from two volunteers with LCA and from their unaffected family members. Led by Kamil Kruczek, Ph.D., a postdoctoral fellow in Swaroops lab, they built the complex retina-like tissues in several stages, starting with skin cells, inducing the production of mature photoreceptors and other retinal cells with the genetic profile of each volunteer. As expected, patient organoids made far less light-sensing opsin than the organoids made from unaffected family members.

To carefully control how much CRX gene would be expressed by the recipient photoreceptors, the team re-engineered the CRX promoter so it could be delivered with the CRX gene as part of the gene therapy. A promoter is a neighboring sequence of DNA that controls when and how genes are expressed. The researchers packed the gene and their engineered promoter inside a virus that shuttled them into the organoid photoreceptors.

The teams gene augmentation strategy restored some CRX protein function for organoids from both patients, driving expression of opsins in both types of photoreceptors: rods and cones.

The fact that this strategy worked for both CRX mutations was pretty exciting, said Swaroop. Gene augmentation may be a viable therapy for LCA caused by other autosomal-dominant mutations.

This proof-of-concept gene therapy study is the first step toward a potential treatment for a rare form of LCA, said Brian Brooks, M.D., NEI clinical director and co-author on the study. Its a great example of bench-to-bedside science, when researchers in basic and clinical science collaborate.

The current study was funded through the intramural programs of the NEI and the National Institute of Allergy and Infectious Diseases, both part of NIH. Patient samples were collected at the NIH Clinical Center, clinical trial number NCT01432847.

NEI has protected intellectual property around this technology which is available for licensing and or co-development. Details can be found on the NIH OTT Licensing website: Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies | Office of Technology Transfer, NIH or by contacting NEI Office of Translational Research mala.dutta@nih.gov

Additional authors include: Zepeng Qu, James Gentry, Benjamin Fadl, Linn Gieser, Suja Hiriyanna, Zacahry Batz, Mugdha Samant, Ananya Samanta, Colin Chu, Laura Campello, and Zhijian Wu.

NEI leads the federal governments research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Kruczek K. Qu Z, Gentry J, Fadl BR, Gieser L, Hiriyanna S, Batz Z, Samant M, Samanta A, Chu CJ, Campello L, Brooks BP, Wu Z, and Swaroop A. Gene therapy of dominantCRX-Leber congenital amaurosis using patient stem cell-derived retinal organoids.Stem Cell Reports, January 28, 2020.https://doi.org/10.1016/j.stemcr.2020.12.018

###

Continued here:

Researchers use patients' cells to test gene therapy for rare eye disease - National Institutes of Health

Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer – PRNewswire

CAMBRIDGE, Mass., Jan. 29, 2021 /PRNewswire/ --Exacis Biotherapeutics, Inc., a development-stageimmuno-oncology company working to harness the immune system to cure cancer,today announcedthe addition of Dirk Huebner,MD,as its Chief Medical Officer. Exacis launched in 2020 to develop next generation mRNA-based cellular therapeutics to treat liquid and solid tumors.

Exacis CEO Gregory Fiore MD said, "Dirk is a wonderful addition and a great fit for our management team. His extensive experience in oncology drug development, including antibody related therapies will be instrumental as we build our pipeline to include high performance stealth edited NK and T cells, with and without CARs (ExaNK, ExaCAR-NK and ExaCAR-T). We look forward to Dirk's insights and medical leadership as we build the company and advance our portfolio."

Dr. Huebner joins Exacis from Mersana Therapeutics where he wasthe Chief Medical Officer,oversaw their clinical developmentand helped build thecompany'sclinical infrastructure. Dr Huebnerhas worked in oncology and immuno-oncology drug development and academiafor more than 25 yearsand brings a deep understanding of the needs in the oncology space as well as the ability to successfully deliverproducts to meet those needs.

Commenting on the new role, Dr. Huebner said, "I am thrilled to join the Exacis team and work with best-in-class technology to create innovative, next-generation engineered NK and T cell therapies that have the potential to improve outcomes and treatment experiences for patients with challenging hematologic and solid tumor malignancies."

About Exacis Biotherapeutics

Exacis is a development stageimmuno-oncologycompany focused on harnessing the human immune system to cure cancer. Exacis uses its proprietary mRNA-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors.Exacis was founded in 2020 with an exclusive license to a broad suite of patents covering the use ofmRNA-based cell reprogramming and gene editing technologiesfor oncology.

ExaNK, ExaCAR-NK and ExaCAR-T utilize mRNA cell reprogramming and mRNA gene editing technologies developed and owned by Factor Bioscience. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all global development and commercial rights for these investigational candidates.

About T and Natural Killer (NK) Cell Therapies

T and NK cells are types of human immune cells that are ableto recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

SOURCE Exacis Biotherapeutics, Inc.

Link:

Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer - PRNewswire

Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction – Cath Lab…

Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are women

Patient enrollment underway atTheChrist Hospital Health Network in Cincinnati (OH) and Mayo Clinic in Rochester (MN) with additional sites across the United States targeted to open soon

Strong investigator and subject interest driven by the positive results of the Phase 2a ESCaPE-CMD trial reported in spring of 2020

BASKING RIDGE, N.J. (January 29, 2021) Caladrius Biosciences, Inc.,a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that it has treated the first patient in its Phase 2b FREEDOM trial of CLBS16 as a therapy for coronary microvascular dysfunction (CMD) at TheChrist Hospital Health Network in Cincinnati, Ohio. The 105-patient double-blind and placebo-controlled clinical trial is designed to further evaluate the efficacy and safety of intracoronary delivery of autologous CD34+ cells (CLBS16) in subjects with CMD and without obstructive coronary artery disease.

We are very excited about our CLBS16 program as it represents a potential breakthrough in the treatment of CMD, a condition which afflicts millions of patients in the US alone, many of whom are women. As a result, CMD is a womens health issue of emerging importance as currently there are no products with approved labeling for coronary microvascular dysfunction, said David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius. The treatment of the first patient in the FREEDOM trial is an important milestone for our Company and the program and we look forward to completing enrollment by the target of year-end 2021. It is especially noteworthy that even during the COVID-19 pandemic, physicians and patients are active in our trial, denoting the seriousness of the disease and underscoring the lack of available effective treatment for CMD.

Following the outstanding full data results from the ESCaPE-CMD study that I presented at SCAI 2020, we are very excited to participate in the FREEDOM trial, said Timothy D. Henry, M.D., Medical Director of the Carl and Edyth Lindner Center for Research at TheChrist Hospital Health Network. Caladrius CLBS16 program has demonstrated great promise and I am looking forward to seeing how this new therapeutic option can benefit patients with CMD.

For more information on this study, please visitclinicaltrials.gov(identifier: NCT04614467).

If you are a patient or a physician and have questions about eligibility for this study, please visitwww.freedom-trial.com.

About Coronary Microvascular Dysfunction

Coronary microvascular dysfunction is a type of non-obstructive coronary artery disease that causes decreased blood flow to the heart muscle that affects approximately 8.3 million people in the U.S.1,2With common symptoms that include recurring, debilitating chest pain, tiredness, and shortness of breath, many CMD patients are undiagnosed because of the absence of large vessel obstruction. Due to an under appreciation of the disease, patients, the majority of whom are women, often go years without proper treatment. When a diagnosis of CMD is missed, patients are untreated and remain at high risk of heart attack and/or cardiovascular-related death._______________________[1] Mittal, S.R.; Indian Heart Journal, Volume 66, 2014, Pages 678681[2] Cleveland Clinic/AHA (American Heart Association)

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Companys current product candidates include: HONEDRA (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (CLI) based on the results of an ongoing clinical trial; OLOGO (formerly CLBS14), a Regenerative Medicine Advanced Therapy (RMAT) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the FDA) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (NORDA); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (CMD); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (CKD). For more information on the company, please visitwww.caladrius.com.

Read more here:

Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction - Cath Lab...

Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19 – PRNewswire

METUCHEN, N.J., Jan. 25, 2021 /PRNewswire/ -- Tevogen Bio today announced it has secured necessary funding from HMP Partners of New Jersey, an investment firm managed by medical doctors, which will allow Tevogen to support all clinical trials of its investigational, potentially curative COVID-19 treatment. Tevogen's Investigational New Drug (IND) application for its proprietary antigen-specific T cell therapy is under review by the U.S. Food and Drug Administration (FDA).

All COVID-19 therapeutics utilized to date have sought to slow the progression of the infection and/or moderate its symptoms. These approaches buy time for the patient's own T cells to activate and respond to the infection, which is the mechanism that the body employs to rid itself of viruses such as the SARS-CoV-2.

In the upcoming trials, Tevogen will study its investigational treatment, TVGN-489, allogeneic T cells that have been programmed and grown in the laboratory, for its safety and capability to recognize and destroy COVID-19 infected cells. Lead investigator Dr. Neal Flomenberg, Chair of the Department of Medical Oncology at Thomas Jefferson University, stated his optimism, "We're excited by the purity and potency of the cells we've been able to generate in the lab. Based on prior experience with these sorts of cells in other settings, we're very hopeful that they will be both safe and effective when the clinical trials are launched."

HMP Partners is supporting Tevogen's efforts to develop a curative treatment due to concerns over recent COVID-19 mutations and the current lack of curative options for this deadly infection. HMP CEO Dr. Manmohan Patel, a prominent pulmonary and critical care specialist, said, "We believe it's imperative to create a curative treatment that is not expected to be compromised by mutations." He added, "Unmodified virus specific T cells are well established as being effective and safe at treating viral infections, which is why we are supporting Tevogen's efforts to develop a much-needed COVID-19 cure."

While Tevogen has raised private investment from HMP Partners to launch its clinical trials, the company is seeking government funding to expedite capacity to manufacture at the scale necessary to develop pandemic-level product supply, just as have a number of vaccine and antibody manufacturers.

Tevogen's proprietary solution is designed to enable a single donation from a donor to generate more than a thousand doses of COVID-19 specific cytotoxic T cells.Yale-trained infectious disease epidemiologist Dr. Ryan Saadi is leading Tevogen's efforts and is among those who are financing the trials. Dr. Saadi stated, "We halted our pursuit for an oncology cure in order to focus solely on COVID-19, and our manufacturing efficiencyand agile business model will allow us to deliver a cure that will be affordable and accessible to all."

About Tevogen Bio

Tevogen Bio was formed after decades of research by its contributors to concentrate and leverage their expertise, spanning multiple sectors of the healthcare industry, to help address some of the most common and deadly illnesses known today. The company's mission is to provide curative and preventative treatments that are affordable and scalable, in order to positively impact global public health.

About HMP Partners

HMP Partners of New Jersey is a consortium of medical doctors who are dedicated to supporting the advancement of potentially life-saving technologies. HMP CEO Dr. Manmohan Patel, a prominent pulmonary and critical care specialist, has nearly 50 years of medical expertise in a diverse field of specialties, including pulmonary, internal, geriatric and emergency medicine as well as critical care. Dr. Patel's commitment to community and medical management is demonstrated by his distinguished appointments, including serving as the Director of Post Cardiac Surgery at Saint Michael's Medical Center in Newark, NJ and as Chairman of the Department of Medicine at Meadowlands Hospital Medical Center in Secaucus, NJ. In 2000, he was appointed by the Governor of New Jersey to the Board of Medical Examiners Executive Committee for the state and served on various other committees, including reviewing malpractice actions, in that capacity.

About Dr. Neal Flomenberg

Dr. Neal Flomenberg is the Chairman of the Department of Medical Oncology and Deputy Director of the Sidney Kimmel Cancer Center at Jefferson University in Philadelphia.Dr. Flomenberg launched Jefferson's Blood and Marrow Transplantation (BMT) Program in 1995. Throughout his four decades of practice, he has maintained a longstanding interest in the immunogenetics and immunology of stem cell transplantation, with the goal of making transplantation safer and more widely available. He is board certified in the fields of internal medicine, hematology, and medical oncology.

Media Contacts:

Mark Irion

[emailprotected]

Katelyn Petroka[emailprotected]

SOURCE Tevogen Bio

See original here:

Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19 - PRNewswire